NEW YORK (GenomeWeb) – Trovagene announced today that it has completed a reorganization effort that it believes will allow it to refocus its efforts on the global distribution of liquid biopsy kits and systems to clinical research laboratories.

The company — which also cut 20 jobs — estimated that the staff reductions, combined with a lowering of expenses associated with marketing CLIA lab testing directly to medical professionals, will reduce its annual pre-tax expenses by approximately $4 million.